Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension
Shots: AstraZeneca (AZ) will receive $5M option license fee and additional $20M on approval of Duaklir (aclidinium / formoterol) (product of AZ) from Circassia. Circassia to get US commercialization rights for Tudorza (aclidinium) AZ has also filled sNDA for Tudorza to the US FDA on basis of ASCENT study results, with expected PDUFA date 31 […]Read More
